Clinical trials: Herpangina
Hand, Foot and Mouth Disease, Herpangina
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design.
- Trial name
- NCT06063057
- Testing
- low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hand, Foot, and Mouth Disease(HFMD), Herpangina
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in…
- Trial name
- NCT07611513
- Testing
- Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hand, Foot, and Mouth Disease (HFMD), Herpangina
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
The trial aims to assess the tolerability, safety, and immunogenicity of the tetravalent inactivated enterovirus vaccine in adults and children aged 6 months to 12 years.
- Trial name
- NCT06754384
- Testing
- Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
- Where
- China
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd